Protein Degradation & Targeting Undruggables Congress 2023

Protein Degradation & Targeting Undruggables Congress

DOWNLOAD THE AGENDA
Boston, USA
15-16 March, 2023

“This was a really great event with a good mixture of new TPD research data and information about relevant industry platform technologies.”

Katherine Donovan, Lead Scientist, Fischer Lab

Who Will be there

TESTIMONIALS

SPEAKERS

 

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer

Adam Gilbert

Executive Director, Head of Design and Synthesis Sciences
Pfizer
 

Amit Choudhary

Assistant Professor, Scientific Founder
Harvard Medical School/Photys Therapeutics

Amit Choudhary

Assistant Professor, Scientific Founder
Harvard Medical School/Photys Therapeutics

Amit Choudhary

Assistant Professor, Scientific Founder
Harvard Medical School/Photys Therapeutics
 

Beth Hoffman

Founder & CEO
Origami Therapeutics

Beth Hoffman

Founder & CEO
Origami Therapeutics

Beth Hoffman

Founder & CEO
Origami Therapeutics
 

Brian Albarran

SVP, Head of Corporate Strategy
Kymera Therapeutics

Brian Albarran

SVP, Head of Corporate Strategy
Kymera Therapeutics

Brian Albarran

SVP, Head of Corporate Strategy
Kymera Therapeutics
 

Charly Chahwan

Co-founder & CSO
SyntheX

Charly Chahwan

Co-founder & CSO
SyntheX

Charly Chahwan

Co-founder & CSO
SyntheX
 

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette received her B.A. from Columbia University, Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying Wnt signaling pathway.  She has been at Promega Corporation for 15 years and is currently an R&D Group Leader of Functional Proteomics.  She leads a team developing technologies and performing research to understand dynamic intracellular interactions within the focus areas of epigenetics, targeted protein degradation, and drug discovery.

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette Daniels, Ph.D.

VP, Protein Degrader Platform
Foghorn Therapeutics

Danette received her B.A. from Columbia University, Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying Wnt signaling pathway.  She has been at Promega Corporation for 15 years and is currently an R&D Group Leader of Functional Proteomics.  She leads a team developing technologies and performing research to understand dynamic intracellular interactions within the focus areas of epigenetics, targeted protein degradation, and drug discovery.

 

Daniel Nomura

Professor, Founder
UC Berkeley/Vicinitas Therapeutics

Dan Nomura is a professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D.

Daniel Nomura

Professor, Founder
UC Berkeley/Vicinitas Therapeutics

Daniel Nomura

Professor, Founder
UC Berkeley/Vicinitas Therapeutics

Dan Nomura is a professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology with Professor John Casida at UC Berkeley and was a postdoctoral fellow at The Scripps Research Institute in chemical physiology with Professor Ben Cravatt before returning to UC Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, the Department of Defense Breakthroughs Award, and the Mark Foundation for Cancer Research INSPIRE award. Research in the Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to discover new disease therapies. 

 

Gisele Nishiguchi

Lead Scientist, Group Leader
St. Jude Children's Research Hospital

Gisele Nishiguchi

Lead Scientist, Group Leader
St. Jude Children's Research Hospital

Gisele Nishiguchi

Lead Scientist, Group Leader
St. Jude Children's Research Hospital
 

Gwenn Hansen

CSO
Nurix Therapeutics

Gwenn Hansen

CSO
Nurix Therapeutics

Gwenn Hansen

CSO
Nurix Therapeutics
 

Helai Mohammad

VP, Head of Biology
Proteovant Therapeutics

Helai Mohammad

VP, Head of Biology
Proteovant Therapeutics

Helai Mohammad

VP, Head of Biology
Proteovant Therapeutics
 

Ian Churcher

CSO
Amphista Therapeutics

Ian Churcher

CSO
Amphista Therapeutics

Ian Churcher

CSO
Amphista Therapeutics
 

Jean Bernatchez

PhD, Senior Scientist and San Diego R&D Group Leader, Research & Development
Eurofins Discovery

Jean Bernatchez

PhD, Senior Scientist and San Diego R&D Group Leader, Research & Development
Eurofins Discovery

Jean Bernatchez

PhD, Senior Scientist and San Diego R&D Group Leader, Research & Development
Eurofins Discovery
 

Jean-Christophe Harmange

CSO
Triana Biomedicines

Jean-Christophe Harmange

CSO
Triana Biomedicines

Jean-Christophe Harmange

CSO
Triana Biomedicines
 

Jing Li

Principal Scientist
Genentech

Jing Li

Principal Scientist
Genentech

Jing Li

Principal Scientist
Genentech
 

Jing Liu

VP, Chemistry
Cullgen

Jing Liu

VP, Chemistry
Cullgen

Jing Liu

VP, Chemistry
Cullgen
 

Kumar Suresh

VP, R&D
Progenra

Kumar Suresh

VP, R&D
Progenra

Kumar Suresh

VP, R&D
Progenra
 

Matthias Brand

Co-Founder & CSO
Proxygen

Matthias Brand

Co-Founder & CSO
Proxygen

Matthias Brand

Co-Founder & CSO
Proxygen
 

Nan Ji

Co-founder, President & CEO
PAQ Therapeutics

Nan Ji

Co-founder, President & CEO
PAQ Therapeutics

Nan Ji

Co-founder, President & CEO
PAQ Therapeutics
 

Niyi Fadeyi

VP, Chemical Sciences
InduPro

Niyi Fadeyi

VP, Chemical Sciences
InduPro

Niyi Fadeyi

VP, Chemical Sciences
InduPro
 

Patrick Gunning

Co-Founder and CSO
Dunad Therapeutics

Patrick Gunning

Co-Founder and CSO
Dunad Therapeutics

Patrick Gunning

Co-Founder and CSO
Dunad Therapeutics
 

Peter Park

CSO
Orum Therapeutics

Peter Park

CSO
Orum Therapeutics

Peter Park

CSO
Orum Therapeutics
 

Saki Ichikawa

Postdoctoral Fellow, Woo Lab
Harvard

Saki Ichikawa

Postdoctoral Fellow, Woo Lab
Harvard

Saki Ichikawa

Postdoctoral Fellow, Woo Lab
Harvard
 

Sam Lievens

Director, Biology
Orionis Biosciences

Sam Lievens

Director, Biology
Orionis Biosciences

Sam Lievens

Director, Biology
Orionis Biosciences
 

Scott Kanner

Co-Founder, Associate Director, Platform Development
Stablix

Scott Kanner

Co-Founder, Associate Director, Platform Development
Stablix

Scott Kanner

Co-Founder, Associate Director, Platform Development
Stablix
 

Simon Bailey

EVP, Head of Drug Discovery
Plexium

As Head of Drug Discovery at Plexium, Simon oversees the company’s efforts to identify novel protein degrader drugs that address significant unmet medical needs. Simon joined Plexium in 2019 bringing more than 25 years’ experience of medicinal chemistry and small molecule drug discovery leadership experience. From 1995-2015, Simon held positions of increasing responsibility at Pfizer including leading the Diabetes and Oncology Medicinal Chemistry Departments. 

Simon Bailey

EVP, Head of Drug Discovery
Plexium

Simon Bailey

EVP, Head of Drug Discovery
Plexium

As Head of Drug Discovery at Plexium, Simon oversees the company’s efforts to identify novel protein degrader drugs that address significant unmet medical needs. Simon joined Plexium in 2019 bringing more than 25 years’ experience of medicinal chemistry and small molecule drug discovery leadership experience. From 1995-2015, Simon held positions of increasing responsibility at Pfizer including leading the Diabetes and Oncology Medicinal Chemistry Departments. 

 

Ted Suh

VP, Chemistry
Orionis Biosciences

Ted Suh

VP, Chemistry
Orionis Biosciences

Ted Suh

VP, Chemistry
Orionis Biosciences
 

Yong Cang

Co-Founder & CSO
Degron Therapeutics

Yong Cang

Co-Founder & CSO
Degron Therapeutics

Yong Cang

Co-Founder & CSO
Degron Therapeutics

Venue Description

Venue

The Royal Sonesta Boston, 40 Edwin Land Boulevard, Cambridge, MA 02142

Discounted rooms available to attendees here

 

DOWNLOAD THE AGENDA

Download the agenda for the Protein Degradation & Targeting Undruggables Congress USA. 

AGENDA

POSTER SUBMISSIONS

Are you looking to showcase your recent work to the undruggables community?

Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster, you need to register as an Academic. 

Please note that there is limited space available, and poster space is assigned on a first-come, first-served basis (subject to checks and successful registration). At the event, your presentation will be displayed in a dedicated poster area. The poster presentation session time of taking place is to be confirmed.

Poster abstract submission deadline is 7pm (EST) on Tuesday January 31 2023

Posters should be a one page PDF in portrait orientation.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible! Academics that submit a poster abstract before January 31 2023 get a 5% discount using the code POSTER5.

Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

If you have any questions please contact [email protected].

Click HERE to make a submission.

HOW TO GET INVOLVED

PARTNER WITH US

It's never too early to get involved! Based on your objectives, we can create bespoke packages designed specifically for you.

From presenting your expertize on the main stage to hosting roundtables. Partner with us to showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

Discuss your objectives by getting in touch: [email protected] 

REGISTER AS A DELEGATE

The Protein Degradation and Targeting Undruggables Summit is the only industry-led forum giving you in-person insight into the full range of novel therapeutic approaches targeting the undruggable and expanding the scope of therapeutically reachable targets.

Step into interactive discussions and engaging presentations on the hottest challenges facing the industry today. 

OR DOWNLOAD THE AGENDA HERE.

Why Attend

The event will allow you to have in-depth conversations on the latest in vitro and in vivo data driving forward the translation of undrugged research into clinically and commercially viable products.

This open forum is a unique opportunity to gather with leading biopharma, expert academic centers and innovative service providers to discuss and share R&D strategies for progressing novel modalities at the frontier of drug discovery.

  1. Get the latest clinical and pre-clinical developments in targeted protein degraders to optimise the clinical landscape
  2. Uncover emerging modalities and new therapeutic targets to develop your commercial pipeline
  3. Discover emerging strategies to induce TPD outside of PROTACs and molecular glues
  4. Hear case studies in PROTAC-mediated protein degradation to develop an understanding of bioavailability and PK to inform your R&D projects
  5. Understand how leading pharma use proteomics strategies, PKPD mechanistic modeling, and AI to assess protein degrader modality

Partners

Platinum Partner

Gold Sponsor

Silver Sponsor

Exhibitors

Media Partners

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Next price increase in

Saturday, January 14, 2023 to Saturday, February 18, 2023
Tier 1 - Academics
$1099
Researchers working solely at an academic institute or hospital
Saturday, January 14, 2023 to Saturday, February 18, 2023
Tier 2 - Pharma & Biotech
$1999
Must have a publicly available active pipeline and not provide services to other drug developers/academics
Saturday, January 14, 2023 to Saturday, February 18, 2023
Tier 3 - Service Providers
$3499
Includes consultants, equipment manufacturers, platform technology and service provider companies
Preparing registration...

Terms & Conditions

In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.

Resources

Download Resource

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us